Core Scientific, Inc. Form 8-K Summary
Business Context and Reporting Period
Core Scientific, Inc. filed a Current Report on Form 8-K dated August 2, 2023, under Item 5.02 concerning changes in executive and board leadership. The company is incorporated in Delaware and maintains principal offices in Austin, Texas. Its common stock and warrants trade on the OTC Pink Marketplace under CORZQ and CORZWQ, respectively.
Leadership Changes
- Michael Levitt resigned as Chief Executive Officer effective August 2, 2023.
- Mr. Levitt became Executive Chairman of the Board at his existing annual base salary of $60,000. His unvested restricted stock units and stock options remain outstanding and eligible to vest while he continues serving on the Board.
- Darin Feinstein resigned as Co-Chairman of the Board effective August 2, 2023, but will remain a director.
- Adam Sullivan, who has served as President since May 15, 2023, was appointed interim CEO effective August 2, 2023. The appointment will continue until the Board appoints a permanent CEO or takes other action.
Financial Metrics and Material Financial Changes
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, operating results, guidance, or other financial metrics. It also does not report a material financial transaction or change in financial condition.
Management Commentary, Risks, and Unusual Items
The filing states that Mr. Levitt’s resignation was not due to any dispute or disagreement with the company or Board regarding operations, policies, or practices. The interim CEO transition creates a management succession matter that investors should monitor, including the timing and terms of any permanent CEO appointment.
The filing states that Mr. Sullivan has no family relationship with the company’s directors or executive officers, no arrangement or understanding regarding his selection as interim CEO, and no reportable related-party transactions with the company.
Key Facts to Verify
- Whether Adam Sullivan is appointed permanent CEO or replaced, and the timing of that decision.
- Whether the executive transition affects business operations, restructuring activities, financing, or strategic plans.
- The continuing compensation and equity-award terms applicable to Michael Levitt as Executive Chairman.
- Current financial condition, liquidity, debt obligations, and operating performance, which are not disclosed in this filing.
- Trading status and market information for the company’s securities on the OTC Pink Marketplace.